🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesA1C target achievement rates — looking for input Page 2

A1C target achievement rates — looking for input

SurmountFan_IN Tue, Oct 14, 2025 at 4:01 PM 30 replies 1,086 viewsPage 2 of 6
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Oct 14, 2025 at 6:51 PM#6
Everything A1cChaser said is correct. I'd also note that A1c has some known limitations: - Iron deficiency can falsely elevate A1c - Recent blood loss or transfusion can falsely lower it - Hemoglobin variants (common in certain ethnic groups) can skew results - Kidney disease affects red blood cell turnover and A1c accuracy For prediabetic patients on GLP-1 therapy, I often find fasting insulin and HOMA-IR more sensitive early markers of improvement than A1c. If your fasting glucose dropped, your insulin sensitivity is improving. The A1c will follow. Also — congratulations to everyone in this thread. These numbers represent real metabolic healing.
15 13SaraMom3, Dr.MetabolicMD, RetaRick_CA and 12 others
Reply Quote Save Share Report
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
Oct 14, 2025 at 7:08 PM#7
Here's my data because I'm obsessed with tracking everything: Tirzepatide, titrated to 15 mg weekly | Timepoint | A1c | FBG | Fasting Insulin | HOMA-IR | |-----------|-----|-----|----------------|---------| | Baseline | 8.4% | 162 | 34.2 µIU/mL | 13.66 | | Month 2 | 7.6% | 138 | 24.1 | 8.20 | | Month 4 | 6.6% | 112 | 14.8 | 4.09 | | Month 6 | 5.8% | 94 | 9.2 | 2.13 | | Month 9 | 5.3% | 88 | 7.1 | 1.54 | The HOMA-IR trajectory is what really tells the story. I went from severe insulin resistance to basically normal. My endo showed this chart to her residents as a teaching case. 😊
19 4TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 16 others
Reply Quote Save Share Report
tammy_FL
Member
234
890
Nov 2024
Tampa, FL
Oct 14, 2025 at 7:25 PM#8
I'll be honest — I was one of those "just eat less and exercise" people until I got diagnosed myself. Humble pie tastes terrible. Semaglutide 2.4 mg (Wegovy) | Timepoint | A1c | |-----------|-----| | Baseline | 6.7% | | 6 months | 5.4% | That's it. Two data points. But going from prediabetic/early T2D to solidly normal in 6 months changed my entire worldview about metabolic disease. This is powerful medicine.
Last edited: Oct 15, 2025 at 1:25 AM
5 14kevin_tulsa, Dr.PainCLE, mike_mealprep and 2 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Oct 14, 2025 at 7:42 PM#9
Coming back to say thank you all for talking me off the ledge. I talked to my doctor and she agreed to add fasting insulin to my next panel. She also said my post-meal glucose readings on my Libre have been trending way down even if A1c hasn't moved yet. Feeling much better about things.
9 21emily_PDX, Dr.SleepRoch, laura_annarbor and 6 others
Reply Quote Save Share Report
steve_okc
Member
489
2,123
Jul 2024
Oklahoma City, OK
Oct 14, 2025 at 7:59 PM#10
That's the spirit Carl! And everyone — keep dropping your numbers in this thread. The more data we collect as a community, the more useful this becomes for people researching GLP-1 therapy. Every data point matters. Let's normalize sharing lab results (while keeping it clear we're not giving medical advice, just sharing experiences). 🔬
Last edited: Oct 14, 2025 at 11:59 PM
17 0KetoKyle, CanadaChris, ZaraB_AL and 14 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register